Repatha (Evolocumab) for ASCVD Secondary Prevention: What Women Need to Know
Evolocumab (Repatha) cuts LDL by up to 60% and reduces major cardiac events. Learn how ASCVD secondary prevention differs for women, dosing, and pregnancy safety.
Read clinical review